Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03251261 · ClinicalTrials.gov registry record
Detection of Cytomegalovirus Virus in Neonates
A clinical trial of CMV, sponsored by Meridian Bioscience.
- Completed
- Registry status
- 1,615
- Enrollment target
- 5
- Study locations
NCT03251261: Completed study of CMV, sponsored by Meridian Bioscience.
NCT03251261 is a study of CMV that has completed, run by Meridian Bioscience. The registered enrollment target is 1,615 participants, above the 132-participant average among 7 other CMV trials with a reported enrollment target (1123% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03251261, a study of CMV, has completed, sponsored by Meridian Bioscience.
- COMPLETED
- Registry status
- 1,615 participants
- Enrollment target
- 5
- Study locations
Study Summary
To evaluate the illumigene CMV assay, using the illumipro-10 with neonates (up to 21 days of age) saliva swabs
Primary Outcome
Test each sample for CMV detection
Conditions Studied
Interventions
- DEVICE illumigene CMV assay, illumipro-10
Study Locations (5)
Alabama
- University of Alabama at Birmingham - Birmingham
Utah
- University of Utah - Salt Lake City
New South Wales
- The Prince of Wales Hospital - Randwick
British Coloumbia
- British Columbia Children's Hospital / British Columbia Women's Hospital - Vancouver
Province of Bologna
- Ospedale Sant'Orsola - Via Massarenti 19
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,615 participants |
| Start Date | 2017-08-02 |
| Est. Completion | 2018-03-05 |
What the finished NCT03251261 record still lists
NCT03251261 is an observational study that tracks outcomes without assigning an intervention. Its 1,615 participants enrollment target places it among the larger protocols in the corpus, above the 132-participant average among 7 other CMV trials with a reported enrollment target (1123% higher).
The record links to 1 condition, with CMV appearing as the primary indexed condition, and to 1 intervention - of which illumigene CMV assay, illumipro-10 is the first listed.
NCT03251261 lists 5 locations in 5 states (Alabama, Utah, New South Wales).
Frequently Asked Questions
What is clinical trial NCT03251261 about?
NCT03251261 is a clinical study titled "Detection of Cytomegalovirus Virus in Neonates". To evaluate the illumigene CMV assay, using the illumipro-10 with neonates (up to 21 days of age) saliva swabs
What is the current status of trial NCT03251261?
This trial is currently completed. The enrollment target is 1,615 participants. The study started on 2017-08-02. Estimated completion is 2018-03-05.
What conditions does trial NCT03251261 study?
This clinical trial studies the following conditions: CMV.
What interventions are being tested in trial NCT03251261?
The interventions under investigation include: illumigene CMV assay, illumipro-10 (DEVICE).
Who is sponsoring clinical trial NCT03251261?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03251261 being conducted?
This trial has 5 study locations across Alabama, Utah, New South Wales, British Coloumbia, Province of Bologna. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CMV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
RECRUITING
-
CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT
RECRUITING · Phase 2
-
CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients
RECRUITING · Phase 1
-
Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants
ACTIVE NOT RECRUITING · Phase 2
-
De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 3
-
CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06959524 · 1,616 participants · NA
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
- NCT06271590 · 1,605 participants · NA
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI